SPORE in Endometrial Cancer

子宫内膜癌中的孢子

基本信息

批准号：
7934596
负责人：
Paul Joseph Goodfellow
金额：
$ 50万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-18 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7934596
关键词：
Adjuvant Biological Response Modifier Therapy Biometry Cancer Biology Cancer Center Commit Detection Development Diagnosis Endometrial Carcinoma FGFR2 gene Family member Genetic Hospitals Inherited Investigation Lead Malignant Neoplasms Marriage Methylation Mismatch Repair Morbidity - disease rate Outcome Pathology Pathway interactions Patients Play Population Prevention Prognostic Marker Recruitment Activity Recurrence Research Research Personnel Research Priority Research Project Grants Risk Role Signal Transduction Specialized Program of Research Excellence Tissues Training Translational Research Universities Uterine Cancer Uterine Neoplasms Washington Woman Work anticancer research career development clinical practice design follower of religion Jewish improved innovation medical schools mortality novel novel strategies prevent programs therapeutic target

项目摘要

This Specialized Program of Research Excellence (SPORE) in Endometrial Cancer is submitted by Washington University in St. Louis, the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. It includes four research projects, three supportive cores, and research and career development programs. This proposal brings together basic and applied investigators to conduct innovative and diverse translational investigations aimed at preventing, diagnosing and treating endometrial cancer. The four projects in our application have been carefully designed to have significant potential to change clinical practice within five years. Project 1: FGFR2 as therapeutic target in endometrial cancer Project 2: Methylation markers for prognosis in endometrioid endometrial cancers Project 3: Identifying inherited endometrial cancer & the environmental and genetic factors contributing to somatic loss of mismatch repair Project 4: Novel effectors of ERK signaling and their potential roles in the treatment of endometrial cancer The four projects represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University and our collaborators. The critical objectives that we have chosen to focus on are to: 1) improve the treatment of patients with persistent or recurrent endometrial cancer using a molecularly targeted therapy and determine if upfront adjuvant biologic therapies hold promise for improving outcomes in the general endometrial cancer population; 2) develop prognostic markers to help guide the treatment of women with the most common form of uterine tumors, endometrioid endometrial cancer; 3) optimize detection of those women with inherited forms of endometrial cancer so they and their at-risk family members can receive risk-appropriate (intensified) cancer surveillance; and 4) elucidate the role novel effectors of ERK signaling play in uterine cancer and assess opportunities for targeting these in the treatment of endometrial cancers. Three Cores will support these projects: Administration, Tissue & Pathology, and Biostatistics. The Developmental Research Program will support a pathway for continued identification and support of diverse research that could replace or improve current projects, and a Career Development Program will recruit and support candidates committed to training in translational research in endometrial cancer.

这项子宫内膜癌卓越研究专门计划 (SPORE) 由圣路易斯华盛顿大学、巴恩斯犹太医院斯特曼癌症中心和华盛顿大学医学院提交。它包括四个研究项目、三个支持核心以及研究和职业发展计划。该提案汇集了基础和应用研究人员，进行创新和多样化的转化研究，旨在预防、诊断和治疗子宫内膜癌。我们申请中的四个项目经过精心设计，具有在五年内改变临床实践的巨大潜力。项目1：FGFR2作为子宫内膜癌的治疗靶点项目2：子宫内膜样子宫内膜癌预后的甲基化标记物项目 3：识别遗传性子宫内膜癌以及导致体细胞错配修复缺失的环境和遗传因素项目4：ERK信号传导的新型效应物及其在子宫内膜癌治疗中的潜在作用这四个项目代表了选定的子宫内膜癌研究重点与华盛顿大学和我们合作者的优势之间精心选择的结合。我们选择关注的关键目标是：1）使用分子靶向治疗改善持续性或复发性子宫内膜癌患者的治疗，并确定前期辅助生物疗法是否有望改善一般子宫内膜癌人群的预后； 2) 开发预后标志物，帮助指导患有最常见子宫肿瘤（子宫内膜样子宫内膜癌）的女性的治疗； 3) 优化对患有遗传性子宫内膜癌的女性的检测，以便她们及其高危家庭成员能够接受适合风险的（强化）癌症监测； 4) 阐明 ERK 信号传导的新型效应器在子宫癌中的作用，并评估在子宫内膜癌治疗中靶向这些效应器的机会。三个核心将支持这些项目：管理、组织与病理学以及生物统计学。发展研究计划将支持继续识别和支持可以取代或改进当前项目的多样化研究的途径，职业发展计划将招募和支持致力于子宫内膜癌转化研究培训的候选人。